The Belmont Report sets out three ethical principles for research involving human subjects — Respect for Persons, Beneficence, and Justice — and, for each one, a specific practical application. If you are working through required human-subjects training and have hit the question of which principle informed consent belongs to, the short answer is Respect for Persons: informed consent is the Report’s stated application of that principle. But the useful thing to actually learn is not the matching pair — it is why the Report draws the line where it does, because that reasoning is what an IRB applies every time it reviews a protocol.
This guide walks through all three principles, their applications, how each becomes an enforceable requirement under the U.S. Common Rule (45 CFR 46), and the role of the Office for Human Research Protections (OHRP) in overseeing that system.
The three principles and their applications, at a glance
The table below is the core mapping the Belmont Report itself lays out in its “Basic Ethical Principles” and “Applications” sections. Everything after this table explains the reasoning behind each row.
| Principle | What it holds | Practical application | Where it shows up in the Common Rule (45 CFR 46) |
|---|---|---|---|
| Respect for Persons | Individuals should be treated as autonomous agents capable of deliberating about their own choices; persons with diminished autonomy are entitled to additional protection. | Informed consent — and additional safeguards for individuals or groups with reduced capacity to consent for themselves. | § 46.116 (general requirements and required elements of informed consent); Subparts B, C, and D (additional protections for pregnant women/fetuses/neonates, prisoners, and children). |
| Beneficence | An obligation to (1) not harm participants and (2) maximize possible benefits while minimizing possible harms. | Systematic assessment of risks and benefits before a study may proceed. | § 46.111(a)(1)–(2) (risks minimized through sound design; risks reasonable in relation to anticipated benefits and the knowledge to be gained). |
| Justice | The benefits and burdens of research should be distributed fairly; no group should be selected as subjects simply because they are easy to recruit or unable to object, and no group should be systematically denied the chance to benefit from research. | Equitable selection of subjects. | § 46.111(a)(3) (equitable selection of subjects, with regard to the purposes of the research and the setting in which it is conducted). |
Respect for Persons: why informed consent is its application
The Belmont Report grounds Respect for Persons in two separate convictions that work together rather than one simple rule: first, that individuals capable of deliberation about their own choices ought to be treated as autonomous agents, meaning their considered decisions are respected even when a researcher might judge the decision unwise; second, that persons with diminished autonomy are entitled to protection, which can mean excluding them from participation or, more often, building extra safeguards around how their participation is authorized.
Informed consent is the mechanism that operationalizes the first half of that principle: it is how a competent adult exercises autonomy over whether to become a research subject at all. That is precisely why, when a training module or exam asks which Belmont principle informed consent is an application of, the answer is Respect for Persons and not Beneficence or Justice — consent is about who gets to decide, not about weighing risk against benefit (that is Beneficence) and not about who is chosen to be asked in the first place (that is Justice). The Common Rule turns this into a specific, auditable requirement at 45 CFR 46.116, which lists the required elements of consent — disclosure of the research’s purpose and procedures, foreseeable risks, expected benefits, alternatives, confidentiality protections, and voluntariness free of coercion or undue influence. For a full walkthrough of those elements and how they’re implemented, see the companion guide on informed consent in research, and on the specific, narrower circumstances where an IRB can waive some or all of them, see waiver of informed consent.
Who counts as having “diminished autonomy,” and what protection means for them
The second half of Respect for Persons — protection for those with diminished autonomy — is not a single test but a category the Report leaves deliberately open, later given concrete shape by the Common Rule’s additional-protection subparts. It commonly covers children, who lack the legal capacity to consent for themselves (addressed under Subpart D, which requires parental permission plus the child’s own assent where appropriate); prisoners, whose institutional setting can make refusal difficult even without explicit coercion (Subpart C); people with cognitive or communicative impairments that limit their ability to understand study information; and others in dependent or unequal-power relationships with an investigator, such as students or employees of the research team. Protection does not automatically mean exclusion — it means the IRB must confirm that additional safeguards (surrogate consent, assent processes, independent advocates, more restrictive risk thresholds) are actually in place before approving the study. See vulnerable populations in research for how IRBs operationalize this category in practice.
Beneficence: why it is a risk/benefit assessment, not a consent question
Beneficence in the Belmont Report is not simply “be kind.” It is defined as two general rules: do not harm, and maximize possible benefits while minimizing possible harms. Applied to research, this becomes an obligation on investigators and, independently, on the IRB, to systematically assess a study’s risks and anticipated benefits before it can proceed — not to eliminate risk (research on human subjects that produces useful knowledge is rarely risk-free) but to ensure risk is justified by the value of what the research could learn and is minimized wherever the science allows.
This is a separate judgment from informed consent, and the distinction matters for understanding why the two get different Belmont principles: risk/benefit analysis under Beneficence is the IRB’s own determination, made before a study can proceed at all and applied uniformly to every prospective subject; informed consent under Respect for Persons is the disclosure of that already-evaluated risk/benefit profile to each individual so they can decide for themselves whether to accept it. An IRB cannot approve a study just because subjects are willing to consent to it — the risk/benefit balance has to be independently reasonable first. That determination is codified at 45 CFR 46.111(a)(1)-(2): risks must be minimized through sound research design, and remaining risks must be reasonable in relation to anticipated benefits to subjects (if any) and the importance of the knowledge likely to result.
Justice: equitable selection of subjects, in both directions
The Belmont Report frames Justice as a question about who ought to receive the benefits of research and who ought to bear its burdens. It is easy to read “equitable selection of subjects” as only meaning “don’t over-recruit vulnerable or convenient populations,” and that half is real: the Report specifically criticizes selecting subjects because they are institutionalized, poor, seriously ill, or otherwise unable to resist being enrolled in research that primarily benefits people outside their group — a pattern the Tuskegee Syphilis Study exemplified (see below).
But the Report also states the reverse obligation, which is less often quoted and just as much a part of Justice: research subjects should not be systematically excluded from studies without good scientific reason either, because exclusion can mean being denied access to the direct benefits of participation (early access to a promising intervention, close clinical monitoring) and, at a population level, to the knowledge the research generates about people like them. This is the historical reasoning behind later policy requiring inclusion of women and minority groups in NIH-funded clinical research. In short, equitable selection under Justice means neither over-burdening nor under-including any particular group relative to who stands to benefit from the resulting knowledge. It is codified as its own, distinct IRB approval criterion at 45 CFR 46.111(a)(3), separate from the risk/benefit criterion.
From ethics to regulation: how Belmont becomes an IRB approval checklist
The Belmont Report is not itself a regulation and creates no legal obligations on its own — it is the ethical framework the binding rule was built to operationalize. That binding rule is the Common Rule, codified at 45 CFR Part 46, and its core approval criteria at 46.111 map almost line-for-line onto the three Belmont applications: risk minimization and a reasonable risk/benefit ratio (Beneficence), equitable selection of subjects (Justice), and informed consent obtained and documented as required by 46.116 (Respect for Persons), plus, where subjects are drawn from a population covered by Subparts B, C, or D, the additional protections those subparts require. Every Institutional Review Board (IRB) in the United States reviews protocols against this checklist; see the companion guide on the IRB/REC approval process for how that review actually runs end to end.
Historical context: why the Report exists
The Belmont Report was produced by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, a body Congress created through the National Research Act of 1974. That Act, in turn, was a direct legislative response to the exposure, in 1972, of the U.S. Public Health Service’s Tuskegee Syphilis Study, which had followed several hundred Black men in Macon County, Alabama, with untreated syphilis from 1932 to 1972 — withholding both diagnosis information and, after it became standard treatment in the 1940s, penicillin, so researchers could continue observing the disease’s natural progression. The Commission met over several years, including an intensive four-day session at the Smithsonian Institution’s Belmont Conference Center (the source of the Report’s name), and published its findings in the Federal Register on April 18, 1979. The Report itself names Tuskegee among the reasons the Commission was convened.
Handled plainly rather than as a rhetorical device: the point is not that Tuskegee was one bad study, but that it demonstrated the U.S. research system had no binding, government-wide ethical framework for human-subjects protection at all — investigators’ individual judgment was the only safeguard. The Belmont Report’s three principles were written to close exactly that gap.
OHRP’s role: what it does, and how it differs from FDA oversight
The Office for Human Research Protections (OHRP), part of HHS, is the federal office responsible for the Common Rule’s implementation and compliance oversight for HHS-conducted and HHS-supported human-subjects research (and, more broadly, for research at any institution that has voluntarily committed to Common Rule protections through a Federalwide Assurance). OHRP does not review individual protocols itself — that is the local IRB’s job — but it registers IRBs, administers the Federalwide Assurance (FWA) system institutions sign to commit to Common Rule compliance, issues guidance interpreting the regulations, and runs two distinct compliance-oversight tracks: not-for-cause evaluations (proactive reviews not triggered by any specific complaint) and for-cause investigations (triggered by a substantive allegation of noncompliance). Findings are issued as determination letters to the institution, and remedies operate at the institutional/FWA level — ranging from required corrective action up to restricting or suspending covered research institution-wide in serious cases.
OHRP’s authority runs through the Common Rule and HHS funding/assurance relationships. It is a distinct track from the FDA’s parallel human-subjects regulations at 21 CFR Parts 50 and 56, which apply to research involving products FDA regulates — drugs, biologics, and medical devices — regardless of whether HHS funding is involved at all. A single clinical trial testing an investigational drug is routinely subject to both frameworks at once: the Common Rule/OHRP track if it also receives HHS support or falls under the institution’s FWA, and the FDA track because of the product being studied. The two sets of regulations are closely aligned in substance (both trace back to the same Belmont principles) but are administered by different federal offices with different registration, reporting, and enforcement mechanics.
“Human subjects” vs. “human participants”
The Belmont Report and the Common Rule both use the term “human subjects,” and that is still the operative regulatory term — 45 CFR 46.102 defines it and IRB paperwork is built around it. “Human participants” is not a distinct regulatory category; it is largely a terminology preference, more common in psychology, education, and social-science style guides (including APA style) as a way of emphasizing the person’s active, consenting role rather than framing them as an object of study. When you see “human participants” in a course module or a journal’s author guidelines, it is describing the same regulatory population the Common Rule calls “human subjects” — the shift is in tone and disciplinary convention, not in what protections apply.
Belmont’s three principles vs. the “four principles of biomedical ethics”
It’s easy to conflate the Belmont Report’s three principles with Beauchamp and Childress’s four principles of biomedical ethics (autonomy, beneficence, non-maleficence, and justice), since they overlap heavily and both undergird informed-consent practice. They are not the same framework: Belmont was written specifically to govern U.S. federally funded human-subjects research and splits what Beauchamp and Childress call beneficence into two parts (a combined “do no harm” and “maximize benefit” rule under Belmont’s single Beneficence principle), while folding autonomy into “Respect for Persons” alongside the separate protection-for-diminished-autonomy clause. If you’re looking specifically at how these ideas apply to the consent process itself, see the 4 principles of informed consent.
Frequently asked questions
Informed consent is considered an application of which Belmont principle?
Respect for Persons. The Belmont Report lists informed consent as the direct practical application of Respect for Persons, because consent is the mechanism through which a competent individual exercises autonomous choice about whether to participate — distinct from Beneficence (the risk/benefit assessment) and Justice (equitable selection of who is approached to participate).
What are the Belmont Report’s three principles?
Respect for Persons, Beneficence, and Justice. Each has a corresponding practical application: Respect for Persons is applied through informed consent (and protections for those with diminished autonomy); Beneficence is applied through systematic assessment of risks and benefits; Justice is applied through equitable selection of subjects.
What does OHRP do?
OHRP is the HHS office responsible for Common Rule compliance oversight of HHS-conducted and HHS-supported human-subjects research. It registers IRBs, administers institutions’ Federalwide Assurances, issues regulatory guidance, and conducts both proactive evaluations and for-cause investigations of institutions, issuing determination letters and, where warranted, requiring corrective action.
Is the Belmont Report itself a law?
No. It is an ethical statement, not a regulation, and creates no independent legal obligations. Its principles were operationalized into binding federal regulation through the Common Rule at 45 CFR Part 46.
Does “human participants” mean something different from “human subjects” in the regulations?
No — they refer to the same regulated population. “Human subjects” is the term defined and used in the Common Rule itself; “human participants” is a commonly used alternative phrasing, especially in social-science and APA-style writing, that does not change which protections apply.
